



Patent Application
Attorney Docket No. PC8835E

#6
mf
3/25/03

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Hon. Commissioner for Patents, Washington, D.C. 20231 on this 3rd day of February 2003.

By

(Signature of person mailing)

Erica L. Smith

(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Cameron, et al. :

APPLICATION NO.: 09/820,158

: Examiner: Alton Nathaniel Pryor

FILING DATE: March 28, 2001

: Group Art Unit: 1616

TITLE: Estrogen Agonists/Antagonists for Preventing
Breast Cancer :

Hon. Commissioner for Patents
Washington, D.C. 20231

Sir:

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a).

A fee in the amount of \$180.00 is believed to be due; therefore, please charge Deposit Account No. 16-1445 the appropriate fee. The Commissioner is also authorized to charge any additional fees or credit any overpayment associated with the submission to the referenced deposit account.

Date: 3/3/2003

Pfizer Inc.
Patent Department, MS 8260-1611
Eastern Point Road
Groton, Connecticut 06340
(860) 715-4331

Respectfully submitted,

Todd M. Crissey
Attorney for Applicant(s)
Reg. No. 37,807

03/10/2003 WABDELRI 00000048 161445 09820150

03 FC:1806 180.00 CH